Tradestie Institutional Equity Comparison Engine

CRSP vs CRNX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRNX Overall Edge

CRNX Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crinetics Pharmaceuticals, Inc. (CRNX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus CRNX at N/M Forward P/E and -527.4% operating margin (+2336.3% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against CRNX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs CRNX N/M Fwd P/E
Growth & Margin Winner CRNX
Op Margin -2058.6% vs -527.4% ยท YoY +1325.1% vs +2336.3%
Momentum & Technical Winner CRNX
1Y -20.5% vs +177.2% ยท 52W Pos 1% vs 100%
Options & Structure Winner CRNX
BREAKDOWN (52nd %ile IV) vs UNCLASSIFIED (<1st %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
CRNX NASDAQ
Crinetics Pharmaceuticals, Inc.
Pharmaceutical Preparations
$84.95
+0.13% 1D
Market Cap $9.0B
1M Return +1.71%
1Y Return +177.16%
Forward P/E N/M
Unified AI Score
46.8 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 60.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% CRNX +177.16% Spread: +93.55 pp (CRNX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue CRNX Revenue CRSP Op. Margin CRNX Op. Margin Margin Edge
FY2018 $0M $0M -5087.8% -1182.5% CRNX
FY2019 $290M $0M 16.1% -4512.3% CRSP
FY2020 $0M $0M -49295.5% -105567.6% CRSP
FY2021 $910M N/A 40.8% N/A CRSP
FY2022 $0M N/A -56190.4% N/A CRSP
FY2023 $370M $0M -60.0% -5547.2% CRSP
FY2024 $40M $0M -1250.4% -32613.5% CRSP
FY2025 $0M $10M -18933.6% -6714.8% CRNX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (4) vs CRNX (5)
Institutional Metric CRSP CRNX Criterion Row Winner
Market Capitalization Scale $4.1B $9.0B Larger Scale CRNX
Trailing P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% +2336.3% Higher Growth CRNX
Operating Margin (TTM) Profitability -2058.6% -527.4% Higher Margin CRNX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -25.6% -42.4% Higher ROE CRSP
52-Week Range Position Momentum 1% ($40โ€“$63) 100% ($30โ€“$85) Stronger Trend CRNX
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 0.29ฮฒ ยท 2% Vol Lower Realized Risk CRNX
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 46.8 / 100 (HOLD) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs CRNX Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRNX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live CRNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor CRNX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.